Document is current
Any future updates will be listed below
-
Authors
Lin, Kevin H.
Rutter, Justine C.
Xie, Abigail
Pardieu, Bryann
Winn, Emily T. http://orcid.org/0000-0001-6759-5406
Bello, Reinaldo Dal
Forget, Antoine
Itzykson, Raphael
Ahn, Yeong-Ran
Dai, Ziwei http://orcid.org/0000-0002-0858-638X
Sobhan, Raiyan T.
Anderson, Gray R.
Singleton, Katherine R.
Decker, Amy E.
Winter, Peter S.
Locasale, Jason W. http://orcid.org/0000-0002-7766-3502
Crawford, Lorin http://orcid.org/0000-0003-0178-8242
Puissant, Alexandre http://orcid.org/0000-0002-3997-9282
Wood, Kris C. http://orcid.org/0000-0002-5887-2253
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA207083, F30CA206348, R01CA207083, R01CA207083, R01CA207083, R01CA207083, R01CA207083, R01CA207083, R01CA207083, R01CA207083)
U.S. Department of Health & Human Services | National Institutes of Health (T32GM007171)
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 11 February 2020
First Online: 16 March 2020
Competing interests
: J.W.L. serves on the scientific advisory board and owns equity in Nanocare Technologies and Raphael Pharmaceuticals. R.I. has received previous funding from Oncoethix SA for work on the bromodomain inhibitor OTX015. The remaining authors declare no competing interests.
